Neurolief Prepares For Launch Of Its ProlivRx System For Major Depressive Disorder With Strategic Investment From BrainsWay

Neurolief, a brain stimulation company specializing in non-invasive neuromodulation therapies that can be administered at a clinic or at home, announced a strategic investment from BrainsWay Ltd., which offers non-invasive neurostimulation treatments for mental health disorders. This investment marks a milestone as Neurolief awaits Food and Drug Administration (FDA) approval and prepares for the commercial launch of its ProlivRx, designed for the treatment of major depressive disorder (MDD). Both companies are dedicated to expanding access to innovative, clinically validated, and non-invasive mental health treatments, the announcement stated. Financial terms of the announcement were not disclosed.

By delivering . . .